The mRNA-based vaccine has been developed in partnership with Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC).

•Gennova Biopharmaceuticals Ltd., which is a Pune-based biotechnology company, had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO) and the Centre's National Regulatory Authority (NRA).

•The Vaccine Subject Expert Committee had then reviewed the interim Phase I data and found HGCO19 to be safe, tolerable and immunogenic among the participants of the study.
https://www.jagranjosh.com/current-affairs/indias-first-mrna-covid-...